News & Commentary

DNA testing firm 23andMe avoids bankruptcy with an announcement on 19 May 2025 that it will be bought by US biotechnology company Regeneron Pharmaceuticals for $256 million (approximately £192 million). Regeneron Pharmaceuticals plans to operate 23andMe and continue all consumer genome services as a wholly-owned company subsidiary. However, this continues to raise questions for 15 million users worldwide about what will happen to their genetic information?

On 10 May 2025 Louisa Ghevaert attended the Growing Families UK and EU Surrogacy and Donor Conception Conference 2025, together with an industry professional networking event on 9 May 2025 in London. This brought together fertility, surrogacy agency, academic and legal experts from around the world, as well as past and present intended parents building families through fertility treatment, international surrogacy and donor conception.

Louisa Ghevaert was delighted to attend the launch event of WEALTH: Women In Health in partnership with Covington & Burling LLP on 2 April 2025. Its aim is to build a powerful community of women across the full value chain of health and investment to advance the health, wealth and position of women in the world. WEALTH was created because whilst women drive approximately 80% of major healthcare decisions, women are underrepresented and underserved across the industry and this needs to change.

Louisa Ghevaert was pleased to attend Progress Educational Trust’s event “Is Fertility Treatment A Solution To Population Decline?” on 26 March 2025. Fertility is continuing to decline across the globe and birth rates are steadily falling. Fertility rates are now at the lowest in the UK since World War II. As such, this event looked at a range of factors influencing declining global fertility and birth rates and debated whether fertility treatment can bridge the gap and solve population decline.

On 23 March 2025 came news reports that genetic testing firm 23andMe has filed for bankruptcy following financial difficulties and concerns about data privacy. Its recent decision to file for bankruptcy is aimed at procuring a sale. However, it leaves its 15 million users around the world questioning what will happen to their genetic data?

Louisa Ghevaert had the pleasure of celebrating the Ethica Fertility launch event on 20 March 2025 at Barnby Street in London with other dedicated professionals in the fertility and family building space. Ethica Fertility’s mission is to offer an innovative, more personalised approach to fertility care and reproductive health.

Louisa Ghevaert was delighted to attend the Nuffield Council on Bioethics workshop “Epigenetics in human reproduction” in London on 11 March 2025. This event looked at the use and implications of epigenetics in human reproduction. It considered the inter-relationships between the reproductive environment, epigenome, long-term health and assisted reproductive technologies.